Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate

Vandana Singh
1 min read
1
In this article:

  • Prothena Corporation plc (NASDAQ: PRTA) announced topline data from the Phase 1 single ascending dose (SAD) study for PRX005 for Alzheimer's disease.

  • PRX005 is one of three global neuroscience research and development programs in collaboration between Prothena and Bristol Myers Squibb & Co (NYSE: BMY).

  • Study participants received a single dose of PRX0005 or placebo intravenously (IV) and were followed for up to two months. The data exhibited that all three dose-level cohorts of PRX005 were generally safe and well tolerated.

  • None of the treatment-emergent adverse events (TEAE) were serious. No clinically relevant changes were observed in other safety parameters.

  • PRX005 also met key pharmacokinetic (PK) and immunogenicity secondary endpoints. Plasma drug concentrations of PRX005 increased in a dose-proportional manner.

  • Furthermore, PRX005 exposure in cerebrospinal fluid (CSF) was measured in the high-dose cohort and based on the robust exposure of PRX005 in the CSF.

  • PRX005 had a desirable immunogenicity profile with no persistent PRX005-induced antidrug antibodies observed.

  • Topline results from the Phase 1 MAD trial are expected by year-end 2023.

  • Price Action: PRTA shares are down 3.55% at $54.64 on the last check Wednesday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories